United Therapeutics Corporation

UTHR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009 FY2008
Operating Activities
Net Income $19.5M $-49.3M
Depreciation & Amortization $11.4M $4.5M
Depreciation $10.7M —
Amortization $717.0K —
Stock-Based Compensation $101.0M $28.7M
Net Cash from Operating Activities $99.7M $-40.4M
Investing Activities
Capital Expenditures $95.4M $124.4M
Business Acquisitions $3.6M —
Net Cash from Investing Activities $-162.6M $-181.2M
Financing Activities
Dividends Paid — —
Stock Repurchases — —
Net Cash from Financing Activities $36.5M $213.0M
Net Change in Cash $-29.1M $-9.9M
Free Cash Flow $4.3M $-164.8M
← Newer Page 3 of 3 Older →